Altimmune’s (ALT) “Buy” Rating Reiterated at B. Riley Financial

Altimmune (NASDAQ:ALT)‘s stock had its “buy” rating reiterated by investment analysts at B. Riley Financial in a research note issued to investors on Friday, Benzinga reports. They currently have a $11.00 target price on the stock, down from their previous target price of $13.00.

ALT has been the topic of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a research note on Monday, September 21st. HC Wainwright restated a “buy” rating on shares of Altimmune in a research note on Tuesday, July 28th. Finally, Evercore restated an “outperform” rating on shares of Altimmune in a research note on Wednesday, September 23rd. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $14.00.

Altimmune Stock Up 1.8%

Altimmune stock opened at $1.64 on Friday. The firm has a market cap of $318.82 million, a price-to-earnings ratio of -2.07 and a beta of 0.16. The company has a debt-to-equity ratio of 0.07, a current ratio of 26.78 and a quick ratio of 26.78. Altimmune has a fifty-two week low of $1.60 and a fifty-two week high of $6.44. The firm has a fifty day moving average price of $2.62 and a two-hundred day moving average price of $3.17.

Altimmune (NASDAQ:ALT) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). As a group, analysts forecast that Altimmune will post -0.58 earnings per share for the current year.

Hedge Funds Weigh In On Altimmune

A number of institutional investors and hedge funds have recently bought and sold shares of ALT. R Squared Ltd increased its holdings in shares of Altimmune by 99.6% during the 3rd quarter. R Squared Ltd now owns 26,475 shares of the company’s stock worth $76,000 after purchasing an additional 13,211 shares during the period. StoneX Group Inc. acquired a new position in shares of Altimmune during the third quarter valued at about $46,000. Parallel Advisors LLC lifted its stake in shares of Altimmune by 21,755.0% in the third quarter. Parallel Advisors LLC now owns 8,742 shares of the company’s stock valued at $25,000 after buying an additional 8,702 shares during the period. Alps Advisors Inc. lifted its stake in shares of Altimmune by 29.6% in the third quarter. Alps Advisors Inc. now owns 255,875 shares of the company’s stock valued at $732,000 after buying an additional 58,501 shares during the period. Finally, IPG Investment Advisors LLC bought a new stake in shares of Altimmune in the third quarter valued at about $29,000. Institutional investors own 78.05% of the company’s stock.

More Altimmune News

Here’s some of the latest news about ALT:

• Positive Sentiment: Results published from the 48-week Phase 2b IMPACT study showed significant improvements versus placebo across measures of liver fat, inflammation and fibrosis, alongside weight loss and generally favorable tolerability. The findings support development of pemvidutide for MASH, though the drug remains investigational. Altimmune announces IMPACT Phase 2b 48-week data
• Positive Sentiment: Altimmune reported $480 million in cash, cash equivalents and investments as of September 30. A report said the balance is expected to fund operations through 2029, easing—but not eliminating—near-term financing concerns as key trials advance. Altimmune outlines cash runway and trial milestones
• Negative Sentiment: A Seeking Alpha opinion argued pemvidutide’s development may be too late and capital-intensive, underscoring concerns about competition, costs and the time required to reach commercialization. Altimmune: Still Too Late and Too Capital-Intensive

About Altimmune

Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune’s work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine.